Oasmia Pharmaceutical AB
Oasmia change to Mid Cap segment at Nasdaq Stockholm
Oasmia Pharmaceutical AB 17.12.2014 08:44 Dissemination of a Adhoc News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Uppsala, Sweden, 2014-12-17 08:44 CET (GLOBE NEWSWIRE) -- UPPSALA, SWEDEN - December 17, 2014. Oasmia Pharmaceutical AB (publ) announced today that from January 2, 2015, the company will be listed at the Mid Cap segment of Nasdaq Stockholm. The move is made possible after Nasdaq's annual review of its Nordic market capitalization (market cap) segments. The Mid Cap list includes companies with a market cap between EUR 150 million and EUR 1 billion. 'We are very pleased with the move, since this means that we are now able to attract potential investors that are not permitted to invest in companies in the Small Cap segment', commented Julian Aleksov, President and CEO of Oasmia. About Oasmia Pharmaceutical AB Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365). Anders Lundin, CFO Mobile: +46 70 209 63 00 E-mail: anders.lundin@oasmia.com News Source: NASDAQ OMX 17.12.2014 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Oasmia Pharmaceutical AB Sweden Phone: Fax: E-mail: Internet: ISIN: SE0000722365 WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden